Overall, more than 50 sales representatives are expected to promote both EstroGel
, Estrasorb, Climara and Vivelle DOT are among the transdermal options approved by the FDA in the United States.
David Dodd, Chairman, CEO at Aeterna Zentaris stated, "This co-promotion agreement is an important step in our strategy of transitioning into a commercially operating specialty biopharmaceutical company; the co-promotion of ASCEND's EstroGel
will jump start our commercial activities, while the FDA continues its active NDA review for the approval of Macrilen in the evaluation of AGHD.
With a focus on establishing revenues and profitability while optimizing resources to reduce its burn rate, the Company co-promotes a non-patch estrogen replacement therapy, EstroGel
, in specific U.
Chairman and CEO of Aeterna Zentaris, David Dodd, stated that during FY14 the company achieved significant progress in the implementation of its strategy of transitioning into a commercially operating specialty biopharmaceutical company, as Aeterna Zentaris put its commercial structure in place, built a full-time contract sales force of 19 representatives, signed a co-promotion agreement with ASCEND and started selling its product EstroGel
in its specific territories in the U.
The study continues to enroll and follow patients and the protocol has been amended to include the use of estrogel
with XYOTAX to determine safety and if efficacy is enhanced.